Integrating Blood-Based, CSF and Imaging Biomarkers With Digital Tools and AI in MCI & AD, AD/PD™ Session Spotlight

In this episode, we dive into one of the most forward-looking conversations from the AD/PD™ 2025 International Conference — Forum Discussion 2, "Integrating Blood-Based, CSF and Imaging Biomarkers With Digital Tools and AI in MCI & AD."Moderated by Dr. Oskar Hansson (Sweden) and Dr. Melissa Murray (USA), this dynamic session was led by Dr. Rhoda Au (USA), Prof. Charlotte Teunissen (Netherlands), Dr. Danielle Graham (USA), Dr. Bryan Cobb (USA) and Dr. Tobias Bittner (Switzerland). The discussion explored how emerging biomarkers — from blood-based diagnostics to digital tools powered by AI — are reshaping how we detect and monitor Alzheimer’s disease. But how close are we to true clinical validation?Key highlights include:• The promise of IVD-cleared blood-based tests for amyloid positivity by 2025• Global progress and regulatory differences in the US and Europe• The critical role of clinical guidelines, education, and confirmatory testing• How digital biomarkers may detect cognitive decline earlier than ever• Four intended uses of digital tools in clinical and research settings• Challenges in validating digital measures with the same rigor as biological onesThis episode is relevant for clinicians, researchers, biotech professionals, regulators, and digital health innovators working on early detection and precision medicine in Alzheimer’s disease.This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.https://adpd.kenes.com/